SecBot SecBot
8-K ·Filed Jul 8, 2026

MRNA

Moderna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001682852-26-000134
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Routine board appointment with no immediate trading implications. Monitor for any future strategic shifts, but this filing alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$73.80
T+0 close · Jul 8, 2026 · via day close
Latest settled
+160.94%
T+60 · $192.57
Vs SPY
+158.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 8 $73.80entry
  2. T+1 · 4mo ago +3.74%α +2.89% · $76.56
  3. T+5 · 4mo ago −8.62%α −9.48% · $67.44
  4. T+20 · 3mo ago −23.77%α −27.05% · $56.26
  5. T+60 · 7w ago +160.94%α +158.62% · $192.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Moderna appointed Michael McDonnell, former CFO of Biogen, to its Board of Directors effective July 8, 2026. McDonnell will also serve on the Audit Committee. This is a routine board governance change with no material financial or operational impact.

Key Facts

  • Michael McDonnell appointed to Board of Directors effective July 8, 2026
  • McDonnell formerly served as CFO of Biogen Inc. (Aug 2020, Feb 2025) and previously at IQVIA, Intelsat, MCG Capital, and EchoStar
  • McDonnell will serve as Class II director until the 2029 annual meeting and on the Audit Committee
  • David Rubenstein moved off the Audit Committee to the Nominating and Corporate Governance Committee

Financial Impact

No financial impact from this board appointment

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
13% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001682852-26-000134
Exhibit: exhibit991-07082026.htm0001682852-26-000134
Document: 0001682852-26-000134-index-headers.html0001682852-26-000134
Document: 0001682852-26-000134-index.html0001682852-26-000134
Document: 0001682852-26-000134.txt0001682852-26-000134

Track record

26 reports on MRNA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026